Page 3 - Nasdaq Phvs News Today

Pharvaris (NASDAQ:PHVS – Get Rating) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average […]

ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated in a Type A meeting...

ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

Pharvaris (NASDAQ:PHVS – Get Rating) shares gapped down before the market opened on Friday . The stock had previously closed at $22.52, but opened at $21.45. Pharvaris shares last traded at $20.65, with a volume of 330 shares. A number of brokerages have recently issued reports on PHVS. SVB Leerink lowered their target price on […]

Pharvaris (NASDAQ:PHVS – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $21.23, but opened at $21.86. Pharvaris shares last traded at $21.86, with a volume of 1 shares. PHVS has been the subject of several analyst reports. Morgan Stanley cut their price target on shares of […]

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...

Pharvaris (NASDAQ:PHVS – Get Rating) had its target price cut by investment analysts at Morgan Stanley to $40.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 127.92% from […]

Zacks Investment Research lowered shares of Pharvaris (NASDAQ:PHVS – Get Rating) from a buy rating to a hold rating in a report issued on Saturday morning, Zacks.com reports. According to Zacks, “Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor […]